4.7 Review

CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope

期刊

CANCER CELL INTERNATIONAL
卷 22, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12935-022-02654-3

关键词

CRISPR; Cas9; Breast cancer; Gene editing; Immunotherapy; Diagnosis; Drug resistance

类别

向作者/读者索取更多资源

Cancer is a major cause of death globally, with breast cancer being the most common type affecting women worldwide. Various treatment strategies, including gene therapy using CRISPR/Cas9, are being explored to improve outcomes for breast cancer patients by targeting drug resistance and enhancing immunotherapy.
Cancer is one of the major causes of mortality worldwide, therefore it is considered a major health concern. Breast cancer is the most frequent type of cancer which affects women on a global scale. Various current treatment strategies have been implicated for breast cancer therapy that includes surgical removal, radiation therapy, hormonal therapy, chemotherapy, and targeted biological therapy. However, constant effort is being made to introduce novel therapies with minimal toxicity. Gene therapy is one of the promising tools, to rectify defective genes and cure various cancers. In recent years, a novel genome engineering technology, namely the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein-9 (Cas9) has emerged as a gene-editing tool and transformed genome-editing techniques in a wide range of biological domains including human cancer research and gene therapy. This could be attributed to its versatile characteristics such as high specificity, precision, time-saving and cost-effective methodologies with minimal risk. In the present review, we highlight the role of CRISPR/Cas9 as a targeted therapy to tackle drug resistance, improve immunotherapy for breast cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据